Table 3.
Adverse events experienced by non-small cell lung cancer patients following treatment with ICIs and RT.
| Grade 1-5 | Grade 3-5 | Grade 5 | |
|---|---|---|---|
| Pulmonary | |||
| Pneumonitis | 28.53% (95% CI: 19.22%-38.88%, I2: 92.00%) |
5.82% (95% CI: 3.75%-8.32%, I2: 57.90%) |
0%-4.76% |
| Dyspnea | 46.06% (95% CI: 25.58%-66.54%, I2:95.3%) |
1.47% (95% CI: 0.44%-2.50%, I2:14.2%) |
0-0.2% |
| Cough | 40.09% (95% CI: 20.38%-59.81%, I2:94.6%) |
0%-15% | 0% |
| Hemoptysis | 0.2%-5% | 0%-0.2% | 0%-0.2% |
| Pleural effusion | 7.5% | 0% | 0% |
| Lung infection | 25% | 20% | 0% |
| Pulmonary embolism | 2.7% | 2.7% | 0% |
| Emphysema | 0.21% | 0.21% | 0.21% |
| Respiratory failure | 1.36% (95% CI: 0.00%-4.35%, I2:51.9%) |
1.36% (95% CI: 0.00%-4.35%, I2:51.9%) |
0.2% (95% CI: 0.00%-0.7%, I2:0.0%) |
| Cardiac | |||
| Acute coronary syndrome | 5% | 2.5% | 0% |
| Sinus tachycardia | 2.7% | 2.7% | 0% |
| Atrial fibrillation | 2.7%-5% | 0%-2.7% | 0% |
| Myocardial infarction | 0.21%-2.56% | 0.21%-2.56% | 0.21%-2.56% |
| Heart failure | 2.5% | 2.5% | 0% |
| Cardiac arrest | 0.42% | 0.42% | 0.42% |
| Cardiomyopathy | 0.21% | 0.21% | 0.21% |
| Cardiopulmonary failure | 0.21% | 0.21% | 0.21% |
| Myocarditis | 0.76% | 0.76% | 0% |
| Aortic dissection | 0.21% | 0.21% | 0.21% |
| Pericarditis | 0.25% | 0.25% | 0% |
| Right ventricular failure | 0.21% | 0.21% | 0.21% |
| Gastrointestinal | |||
| Dysphagia | 10%-82.5% | 0% | 0% |
| Esophagitis | 38.51% (95% CI: 6.79%-70.22%, I2:98.5%) |
0%-2.7% | 0% |
| Anorexia | 23.86% (95% CI: 3.02%-44.69%, I2:86.1%) |
0% | 0% |
| Nausea | 30.51% (95% CI: 4.38%-56.64%, I2:92.0%) |
0%-5% | 0% |
| Vomiting | 5% | 0% | 0% |
| Weight loss | 20% | 0% | 0% |
| Constipation | 27.67% (95% CI: 0.0%-58.04%, I2:96.7%) |
0%-2.7% | 0% |
| Diarrhea | 17.30% (95% CI: 13.36%-21.23%, I2:39.0%) |
0.6% (95% CI: 0.0%-1.32%, I2:0%) |
0% |
| Gastric hemorrhage | 2.5%-8.1% | 2.5%-8.1% | 0%-2.7% |
| Elevated liver enzymes | 7.64% (95% CI: 4.65%-11.3%, I2:0.0%) |
7.64% (95% CI: 4.65%-11.3%, I2:0.0%) |
0% |
| Dehydration | 5%-12.5% | 0%-7.5% | 0% |
| Colitis | 4.24% (95% CI: 1.15%-7.34%, I2:0.0%) |
1.52% (95% CI: 0.0%-3.80%, I2:0.0%) |
0% |
| Endocrine | |||
| Hyperthyroid | 10%-10.8% | 0% | 0% |
| Hypothyroidism | 10.73% (95% CI: 5.95%-15.51%, I2:57.8%) |
0.25% (95% CI: 0.0%-0.74%, I2:0.0%) |
0% |
| Adrenal insufficiency | 5.4% | 5.4% | 0% |
| Hematologic | |||
| Anaemia | 5%-47.6% | 2.5%-4.76% | 0% |
| Febrile neutropenia | 2.7%-5% | 2.7%-5% | 0% |
| Neutropenia | 12.5%-38.1% | 2.5%-9.5% | 0% |
| Leucopenia | 47.6% | 4.7% | 0% |
| Thromboembolism | 5% | 2.5% | 0% |
| Hypercalcemia | 2.5%-5% | 0%-2.5% | 0% |
| Other | |||
| Fatigue | 50.97% (95% CI: 25.61%-76.33%, I2:97.7%) |
0%-5% | 0% |
| Alopecia | 35% | 0% | 0% |
| Paresthesia- | 27.5% | 0% | 0% |
| Fever | 32.5%-38.1% | 0% | 0% |
| Back pain | 10.5%-17.5% | 0%-0.21% | 0% |
| Pruritus | 11.58% (95% CI: 7.94%-15.23%, I2:23.8%) |
0% (95% CI: 0.0%-0.29%, I2:0.0%) |
0% |
| Rash | 12.40% (95% CI: 6.47%-18.33%, I2:60.0%) |
0%-5% | 0% |
| Hypertension | 17.5% | 0% | 0% |
| Hypotension | 2.5%-5.0% | 2.5%-5.0% | 0% |
| Dizziness | 15% | 0% | 0% |
| Asthenia | 10.73% | 0.63% | 0% |
| Dermatitis | 16.64% (95% CI: 3.87%-29.41%, I2:88.2%) |
1.32% (95% CI: 0.0%-2.91%, I2:0.0%) |
0% |
| Arthralgia | 8.34% (95% CI: 1.21%-15.47%, I2:85.1%) |
0%-2.7% | 0% |
| Kidney injury | 7.73% (95% CI: 1.35%-18.70%, I2:83.4%) |
0.1% (95% CI: 0.0%-1.08%, I2:10.4%) |
0% |
| Edema | 7.5%-12.5% | 0% | 0% |
| Myalgia | 5%-17.4% | 0%-0.7% | 0% |
| Headache | 3.4%-10.9% | 0%-5.4% | 0% |
| Flu-like Illness | 1.48%-5% | 0% | 0% |
| Infection | 8.23% (95% CI: 1.59%-14.87%, I2:82.7%) |
0.2%-20% | 0% |
| Malaise | 2.4%-10% | 0% | 0% |
| Hypothermia | 2.7% | 2.7% | 0% |
| Myositis | 5% | 0%-5% | 0% |
| Arthritis | 2.17% | 0% | 0% |
| Chills | 5% | 0% | 0% |
| Dysgeusia | 5.0% | 0% | 0% |
| Peripheral neuropathy | 45% | 12.5% | 0% |
| Seizure | 2.7% | 2.7% | 0% |
| Sepsis | 0.2%-2.5% | 0.2%-2.5% | 0%-0.2% |
| Thromboembolism | 1.91% (95% CI: 0.25%-5.07%, I2:25.0%) |
0.27%-2.5% | 0% |
ICIs, Immune checkpoint inhibitors; RT, Radiotherapy.